Composition Of Matter Patents - Pharma

Relevant Publications

Drug discovery efforts toward inhibitors of canonical Wnt/β-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010-2020).

Issue Release: 2021

Off-Patent Drug Repositioning.

Issue Release: 2020

Computer-assisted cognitive remediation therapy for patients with schizophrenia induces microstructural changes in cerebellar regions involved in cognitive functions.

Issue Release: 2019

Glycine transporter-1 inhibitors: a patent review (2011-2016).

Issue Release: 2018

Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).

Issue Release: 2017

Sphingosine kinase inhibitors: a review of patent literature (2006-2015).

Issue Release: 2016

Parallel worlds of public and commercial bioactive chemistry data.

Issue Release: 2014

Do recent US Supreme Court rulings on patenting of genes and genetic diagnostics affect the practice of genetic screening and diagnosis in prenatal and reproductive care?

Issue Release: 2014

Tecfidera(®): an approach for repurposing.

Issue Release: 2014

Protein chaperones: a composition of matter review (2008 - 2013).

Issue Release: 2014

Stearoyl-CoA desaturase inhibitors: update on patented compounds.

Issue Release: 2009

The ethics of patenting human embryonic stem cells.

Issue Release: 2009

The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley.

Issue Release: 2007

Satraplatin: BMS 182751, BMY 45594, JM 216.

Issue Release: 2007

Trends in the human embryonic stem cell patent field.

Issue Release: 2007

Therapeutic switching: a new strategic approach to enhance R&D productivity.

Issue Release: 2005

Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.

Issue Release: 2005

Gadofosveset: MS 325, MS 32520, Vasovist, ZK 236018.

Issue Release: 2004

Patents, medicine, and the interests of patients: applying general principles to gene patenting.

Issue Release: 2003

INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.

Issue Release: 2003

How Does the Patent System Affect Generic Competition?

What are the Implications for Pharma Companies?

What is Patient Education in Pharma?

What Causes Adverse Drug Events?

What is Regulatory Approval?

How Long Does the Approval Process Take?

How Do Pharmacists Contribute to Patient Care?

Why do Pharma Companies Use CROs?

Why is the Management of Chronic Conditions Important?

What Challenges Exist in Patient Education?

Partnered Content Networks

Relevant Topics